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(Miething et al., 2007). This led to the 
identification of Runx3 as a proviral target 
that facilitated tumor relapse upon tar-
geted therapy with imatinib. These new 
mouse models and genomic techniques 
can provide us with unique reagents to 
uncover new resistance mechanisms, 
thereby allowing us to design strategies 
to overcome resistance that can subse-
quently be tested in cancer patients.
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Tumorigenesis is a multistep process that requires constitutive cell division, growth, and survival. One 
strategy used by cancer cells to upregulate growth and survival pathways is through autocrine production 
of growth and survival factors. Two recent papers by Gao et al. and Sansone et al. published in The Journal 
of Clinical Investigation outline the importance of autocrine interleukin 6 (IL-6) in lung and breast cancers 
and implicate IL-6 as an important activator of oncogenic STAT3 in lung adenocarcinomas and of Jagged-
1/Notch signaling in breast tumor mammospheres.IL-6 is a multifunctional cytokine that 
is important for immune responses, 
cell survival, apoptosis, and prolifera-
tion (Kishimoto, 2005). IL-6 signals via 
a heterodimeric IL-6R/gp130 complex, 
whose engagement triggers activa-
tion of Janus (JAK) kinases, and the 
downstream effectors STAT3, SHP-2/
Ras, and PI3K/Akt (Kishimoto, 2005). 
Early studies implicated IL-6 and its 
major effector STAT3 as protumori-
genic agents in many cancers, includ-
ing breast, lung, colon, prostate, ovar-
ian, and hematological cancers as well 
as melanoma; and IL-6 levels are sig-nificantly elevated in lung and breast 
cancer patients, associated with poor 
prognosis (Hodge et al., 2005).
Activating mutations in epidermal 
growth factor receptor (EGFR) were 
found to result in constitutive STAT3 acti-
vation in lung cancer (Gao et al., 2007). 
Although EGFR can also signal to STAT3 
(Quesnelle et al., 2007), pharmacological 
inhibition of its tyrosine kinase activity 
did not prevent STAT3 phosphorylation 
in lung cancer cells, while it significantly 
inhibited Akt and ERK activation (Gao et 
al., 2007). By contrast, complete block-
ade of STAT3 phosphorylation was found Cancer Cupon treatment with pan-JAK inhibitor 
(Gao et al., 2007). The knockdown of 
STAT3 or inhibition of its phosphorylation 
delayed cell growth in culture and tumor 
growth in a xenograft model, underscor-
ing the critical role of phospho-STAT3 in 
lung cancer driven by EGFR. Next the 
authors searched for the signal respon-
sible for JAK and STAT3 activation in 
their system. Cancer cell lines carrying 
EGFR mutations were found to produce 
high amounts of IL-6, and introduction 
of mutated EGFR into breast epithelial 
cells in vitro rapidly induced IL-6 pro-
duction along with cellular transforma-ell 13, January 2008 ©2008 Elsevier Inc. 
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Previewstion. Blockade of IL-6, IL-6R, 
or gp130 completely abro-
gated this EGFR effect. There 
was also a good correlation 
between IL-6 expression 
and STAT3 activation in pri-
mary lung adenocarcinomas 
carrying EGFR mutations. 
Finally, the authors were able 
to show that ectopic expres-
sion of mutant EGFR acti-
vates the IL-6 promoter. In 
conclusion, oncogenic EGFR 
mutations activate transcrip-
tion of IL-6 via an unidentified 
mechanism, and IL-6, acting 
in a paracrine and autocrine 
manner, contributes to cellu-
lar transformation and growth 
via STAT3 phosphorylation 
(Figure 1A).
Using a different approach, 
Sansone et al. also found a 
pivotal role of IL-6 in epithelial 
cancers. Working with mam-
mospheres (MS)—multicel-
lular spheroids, which when 
generated from breast cancer 
cells are enriched in tumor 
progenitors—the investiga-
tors found much higher lev-
els of IL-6 mRNA when MS 
were produced from tumor 
samples rather than normal 
breast epithelium (Sansone 
et al., 2007). IL-6 neutraliza-
tion blocked the self-renewal 
capability of tumor (T)-derived 
MS. The same applied for MS 
generated from MCF-7 cells 
stimulated with IL-6. The most intriguing 
observation made by Sansone et al. is 
that the Notch pathway is a critical down-
stream target of IL-6. Involvement of the 
Notch signaling pathway has been pre-
viously documented in breast cancers, 
and Notch is highly expressed in both 
normal (N)- and T-MS. However, this is 
the first time a relationship between IL-6 
and Notch signaling has been described. 
IL-6 blockade induced a dramatic down-
regulation of Notch-3 gene expression, 
and recombinant IL-6 induced notch-3 
transcription. Notch-3 promoted MS 
survival via its interaction with Jagged-1. 
IL-6 also promoted secretion of Jagged-
1, a cognate ligand for Notch-3 (Sansone 
et al., 2007) (Figure 1B), which has been 
confirmed by knockdown and inhibi-
tion approaches. Upregulation of Notch 
signaling by IL-6 culminated in a protu-
morigenic gene expression program. 
The authors also pointed out that the 
hypoxia resistance gene carbonic anhy-
drase (CA-IX) is activated in breast can-
cer cells by IL-6/Notch/Jagged action 
and provides survival advantages under 
hypoxic conditions. However, it remains 
to be determined whether IL-6-depen-
dent Notch upregulation is also STAT3 
dependent (Figure 1B).
These two studies significantly expand 
our understanding of IL-6 involvement in 
epithelial cancers and stress the impor-
tance of autocrine/paracrine IL-6 signal-
ing along with the work of others (Sasser 
et al., 2007; Yeh et al., 2006). 
These studies also pose sev-
eral mechanistic and concep-
tual questions.
(1) While many normal epi-
thelial cells express gp130, 
they do not express signifi-
cant amounts of IL-6R (Mit-
suyama et al., 2006). It would 
be of interest to investigate 
whether, during malignant 
transformation, tumor cells 
acquire high IL-6R expres-
sion along with IL-6 secre-
tion. Interestingly, tumor-infil-
trating inflammatory/immune 
cells may secrete both IL-6 
and soluble IL-6R, which then 
signal to gp130+ IL-6R− cells, 
a phenomenon called IL-6 
trans-signaling (Mitsuyama et 
al., 2006). Macrophages and 
dendritic cells are potent IL-6 
producers and can be acti-
vated by molecular “danger” 
signals produced by dying 
cancer cells (or in the case 
of lung cancer by tobacco 
smoke or air pollutants) (Karin 
et al., 2006).
(2) The IL-6/STAT3 path-
way induces expression of 
SOCS3, the molecule that 
inactivates IL-6 signaling 
through a negative feedback 
loop (Kishimoto, 2005). While 
SOCS3 expression was not 
analyzed in these studies, 
tumors that rely on continu-
ous autocrine IL-6 signaling 
may evolve a strategy to prevent SOCS3-
dependent inactivation of IL-6 signaling.
(3) Only about 10% of lung cancers 
display EGFR mutations, but up to 50% 
of such tumors contain constitutively acti-
vated STAT3. The mechanism by which 
active EGFR leads to IL-6 induction is not 
known, but the involvement of NF-κB, 
AP-1, C/EBP, and their activating kinases 
can be proposed. Obviously, EGFR is not 
a unique trigger of IL-6 expression in can-
cer cells, and other signaling pathways 
should also lead to IL-6 production, given 
the importance of IL-6 in cancer. While it 
is not known whether the erbB2/HER2 
oncogene can activate the IL-6 gene, acti-
vated Ras, which is observed in 30% of 
lung cancers, may also lead to IL-6 induc-
figure 1. The Role of IL-6 signaling in cancer cells
(A) In lung adenocarcinoma cells, somatic mutations in EGFR activate IL-6 
transcription by an as yet unidentified mechanism. IL-6 is secreted by can-
cer cells and activates STAT3, which sustains tumor growth and proliferation. 
Contribution of infiltrating immune/inflammatory cells in vivo is also possible, 
and they can provide both IL-6 and soluble IL-6R (sIL-6R).
(B) IL-6-dependent STAT3 activation results in numerous downstream events 
required for tumor growth. Sansone et al. found an important role of the IL-6/
Notch/Jagged pathway, which activates expression of the hypoxia resistance 
gene CA-IX. It remains to be determined whether Notch induction by IL-6 
requires STAT3 or the SHP2/Erk pathway. Other IL-6/STAT3-dependent path-
ways include production of IL-6, activation of genes required for cell survival 
and proliferation (c-Myc, Cyclin D, Bcl2), and inactivation of tumor suppressor 
(FoxP3). Cancer Cell 13, January 2008 ©2008 Elsevier Inc.
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Previewstion, as secreted IL-6 has recently been 
shown to be required for Ras-dependent 
carcinogenesis (Ancrile et al., 2007).
(4) Does EGFR-induced IL-6 produc-
tion contribute to tumorigenesis in other 
tissues? An interaction between gp130 
and EGF signaling was noted also in 
breast cancer, and EGFR mutations are 
found in various tumors. Therefore, it 
appears likely that mutated EGFR can 
also induce IL-6-dependent tumorigen-
esis in other cancers, but this requires 
further investigation.
Another interesting question is why 
tumors choose IL-6 to constitutively acti-
vate STAT3? STAT3 can be activated by 
many IL-6-like cytokines and by means of 
crosstalk with other signaling pathways. 
While Onconstatin M and LIF were ruled 
out (Gao et al., 2007), other cytokines 
like IL-11 or IL-22 could also contribute to 
STAT3 phosphorylation and tumor devel-
opment. One plausible hypothesis is that 
immune/inflammatory cells in a close 
interaction with cancer cells are capa-
ble of producing prodigious amounts of 
"start-up" IL-6 (but not other family mem-
bers) required for early tumor promotion.
The last but not the least question that 
arises from these studies concerns the 
importance of the IL-6/STAT3 axis in 
cancer, or in other words, what is the role 
of STAT3 in carcinogenesis? Early stud-
ies on colon cancer implicated STAT3 
as a major regulator of cell proliferation 
and survival, particularly due to its ability 
to regulate expression of c-Myc, Mcl-1, 
Cyclin D, and Bcl-2 (Figure 1) (Becker et 
al., 2005). In chemically induced hepato-
cellular carcinoma (HCC), IL-6 appears to 
play a dual role: on one hand it facilitates 
cell injury and subsequent compensatory 
proliferation of hepatocytes, and on the other hand it provides growth signals to 
transformed hepatocytes (Naugler et al., 
2007). Being part of a positive IL-6 auto-
crine loop, STAT3 could also cooperate 
with NF-κB in IL-6 induction (Figure 1B). 
Importantly, Sansone et al. provide a link 
between IL-6 and Notch in cancer and 
show how IL-6 signaling can eventually 
drive expression of Notch-dependent 
genes. The IL-6, STAT3, and Notch path-
ways synergize in induction of c-Myc, 
but it remains to be determined whether 
the same cooperation extends toward 
expression of other typical IL-6 targets, 
such as Bcl-2 and Cyclin D.
Another idea that awaits experimen-
tal confirmation comes from the stud-
ies of T helper cell differentiation. In T 
cells, IL-6-activated STAT3 antagonizes 
FoxP3 and thus drives differentiation of 
proinflammatory instead of regulatory T 
cells (Dominitzki et al., 2007). A recent 
report reveals FoxP3 within epithelial 
cells as an important tumor suppressor 
in breast cancer acting via repression 
of the erbB2/HER and skp2 oncogenes 
(Zuo et al., 2007). Expression of Foxp3 
and its targets HER2 and SKP2 was not 
analyzed by Gao et al. or Sansone et al., 
so it would interesting to test whether IL-
6/STAT3 could work through a FoxP3-
dependent mechanism in addition to 
previously described Notch and c-Myc 
mechanisms (Figure 1B).
Only a few targeted therapeutics that 
specifically inhibit tumor growth with 
minimal general cytotoxicity are cur-
rently available. However, several drugs, 
including antibodies and soluble recep-
tors that block IL-6 signaling, have been 
developed and are currently in the clinic 
or under clinical trials. The studies by 
Gao et al. and Sansone et al., along with Cancerother recent papers (Becker et al., 2005; 
Naugler et al., 2007), create the rationale 
for anti-IL-6-specific therapy in a variety 
of carcinomas.
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